GSK Consumer's pre-tax profit up 6% in Q2 on controlled raw material costs

According to the company, its domestic business grew 7 per cent, backed by Horlicks' and Boost's performance

Horlicks, GSK Consumer, GSK
Arnab Dutta New Delhi
2 min read Last Updated : Nov 07 2019 | 9:42 PM IST
GlaxoSmithKline Consumer Healthcare (GSKCH), the maker of popular health drinks Horlicks and Boost, on Thursday reported a 5.7 per cent year-on-year (YoY) rise in profit before tax (PBT) in the July-September quarter. The firm’s PBT rose to Rs 451.8 crore from Rs 427.4 crore, as benign raw material prices kept its expenses at check.
 
GlaxoSmithKline Consumer’s revenue from operations remained muted with 5.7 per cent YoY growth. It has reported Rs 1,345 crore revenue in the last quarter, compared to Rs 1,272 crore a year-ago period.
 
According to the company, its domestic business grew 7 per cent, backed by Horlicks’ and Boost’s performance. While the newly launched Horlicks Protein gained momentum in the market, its health food drink portfolio, which leads the market, gained more volume share. Its volume share stood at 65.7 per cent while clocked 55.4 per cent market share by value.
 
“Boost and Horlicks continue to gain significant shares on the back of a strong execution strategy that witnessed an increase in distribution reach to 2.05 million outlets. We continue to drive brand building initiatives through stepped up investments in our brands, innovations and consumer-connect activities,” said Navneet Saluja, managing director at GSKCH.
 
Last quarter’s performance came amid a transformation that GSKCH is undergoing. Horlicks, the largest brand in its portfolio contributing over 80 per cent of its annual sales, is being sold. In December last year, GlaxoSmithKline announced the divestment of Horlicks and other consumer health care nutrition brands to Unilever and the merger of GSKCH with Hindustan Unilever. After securing approvals from the Competition Commission of India and the National Company Law Tribunal, the merger is awaiting further statutory and regulatory approvals.
 


One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Q2 resultsGlaxoSmithKline

Next Story